816 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL http://www.zacks.com/stock/news/416134/roche-gets-fda-nod-for-venclexta-plus-gazyva-to-treat-cll?cid=CS-ZC-FT-416134 May 17, 2019 - Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid http://www.zacks.com/stock/news/416133/celgene-gets-ec-nod-for-label-expansion-of-revlimid-imnovid?cid=CS-ZC-FT-416133 May 17, 2019 - Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer http://www.zacks.com/stock/news/414385/pfizers-bavencio%2Binlyta-combo-gets-fda-nod-for-kidney-cancer?cid=CS-ZC-FT-414385 May 15, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark http://www.zacks.com/stock/news/412897/aveo-pharmaceuticals-aveo-q1-earnings-revenues-miss-mark?cid=CS-ZC-FT-412897 May 11, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark http://www.zacks.com/stock/news/412859/aveo-pharmaceuticals-aveo-q1-earnings-revenues-miss-mark?cid=CS-ZC-FT-412859 May 10, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
Endo (ENDP) Q1 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/412848/endo-endp-q1-earnings-revenues-beat-estimates?cid=CS-ZC-FT-412848 May 10, 2019 - Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/411687/why-bristol-myers-squibb-bmy-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-411687 May 09, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates http://www.zacks.com/stock/news/411124/array-biopharma-arry-q3-earnings-and-sales-beat-estimates?cid=CS-ZC-FT-411124 May 08, 2019 - Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss http://www.zacks.com/stock/news/411021/prothenas-prta-q1-earnings-beat-estimates-revenues-miss?cid=CS-ZC-FT-411021 May 08, 2019 - Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.
5 Stocks With Upgraded Broker Ratings Worth Betting on Now http://www.zacks.com/stock/news/410864/5-stocks-with-upgraded-broker-ratings-worth-betting-on-now?cid=CS-ZC-FT-410864 May 08, 2019 - Brokers have more understanding of fundamentals of a company, and also about the overall economy. So, following broker advice is a wise decision.

Pages: 12345678910...82

<<<Page 5>